New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
It lost $9.9M on $1.6M of revenue: $602.87 for every $100. What is an income statement?
| Revenue | 1.6 | 100.0% |
|---|---|---|
| Cost of revenue | 0.0 | 0.0% |
| Gross profit | 1.6 | 100.0% |
| Research & development | −8.3 | −504.8% |
| Selling, general & admin | −4.2 | −259.1% |
| Operating income | −10.9 | −663.9% |
| Other income, net | +1.2 | 75.2% |
| Income tax | −0.2 | −14.1% |
| Net income | −9.9 | −602.9% |
| Older periods | Sep '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+1 more quarter Free account |
20.11 | 2.23 | 1.92 | 1.64 |
Gross Profit |
20.11 | 2.23 | 1.92 | 1.64 | |
R&D Expenses |
14.42 | — | 8.82 | 8.26 | |
SG&A Expenses |
3.53 | — | 2.49 | 4.24 | |
Operating Income |
2.16 | 2.23 | (9.39) | (10.86) | |
Non-operating Interest Expenses |
0.60 | — | 0.28 | — | |
Non-operating Income/Expense |
(0.36) | — | 3.13 | 1.23 | |
| 1.80 | 2.23 | (6.26) | (9.63) | ||
Income Tax Provision |
0.32 | — | 0.21 | 0.23 | |
Income after Tax |
1.47 | 2.23 | (6.48) | (9.86) | |
Dividends (Preferred) |
— | — | 0.00 | — | |
Net Income Common |
1.47 | (17.35) | (6.48) | (9.86) | |
EPS (Basic) |
0.61 | (7.05) | (2.62) | (0.68) | |
EPS (Diluted) |
0.61 | (7.05) | (2.62) | (0.68) | |
Shares (Basic, Weighted) |
2.43 | 2.46 | 2.48 | 14.50 | |
Shares (Diluted, Weighted) |
2.43 | 2.46 | 2.48 | 14.50 | |
Gross Margin |
100.00% | 100.00% | 100.00% | 100.00% | |
EBIT Margin |
10.74% | 100.00% | (489.83%) | (663.94%) | |
EBT margin |
8.93% | 100.00% | (326.64%) | (588.75%) | |
Net Profit Margin |
7.32% | (776.85%) | (337.70%) | (602.87%) | |
EBITDA |
2.99 | 2.23 | (9.39) | (10.09) | |
EBIT |
2.16 | 2.23 | (9.39) | (10.86) | |
Income from Continuous Operations |
1.47 | (17.35) | (6.48) | (9.86) | |
Income from Discontinued Operations |
— | 0.00 | — | — | |
Consolidated Net Income/Loss |
1.47 | (17.35) | (6.48) | (9.86) | |
EPS (Basic, from Continuous Ops) |
0.61 | (7.05) | (2.62) | (0.68) | |
EPS (Diluted, from Cont. Ops) |
0.61 | (7.05) | (2.62) | (0.68) | |
EPS (Basic, Consolidated) |
0.61 | (7.05) | (2.62) | (0.68) | |
EPS (Diluted, Consolidated) |
0.61 | (7.05) | (2.62) | (0.68) | |
Shares (Diluted, Average) |
— | 2.46 | 2.48 | — | |
EBITDA Margin |
14.85% | 100.00% | (489.83%) | (616.87%) | |
Operating Cash Flow Margin |
(56.15%) | — | — | (687.71%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026